Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.

Ratelade J, Arrondel C, Hamard G, Garbay S, Harvey S, Biebuyck N, Schulz H, Hastie N, Pontoglio M, Gubler MC, Antignac C, Heidet L.

Hum Mol Genet. 2010 Jan 1;19(1):1-15. doi: 10.1093/hmg/ddp462.

PMID:
19797313
2.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

PMID:
12915483
3.

Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.

Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B.

J Am Soc Nephrol. 2007 Mar;18(3):719-29. Epub 2007 Jan 31.

4.

WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.

Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC.

Am J Pathol. 1999 Jan;154(1):181-92.

5.

A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.

Viney RL, Morrison AA, van den Heuvel LP, Ni L, Mathieson PW, Saleem MA, Ladomery MR.

Proteomics. 2007 Mar;7(5):804-15.

PMID:
17295355
6.

A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.

Natoli TA, Liu J, Eremina V, Hodgens K, Li C, Hamano Y, Mundel P, Kalluri R, Miner JH, Quaggin SE, Kreidberg JA.

J Am Soc Nephrol. 2002 Aug;13(8):2058-67.

7.

Glomerular epithelial cell phenotype in diffuse mesangial sclerosis: a report of 2 cases with markedly increased urinary podocyte excretion.

Ikezumi Y, Suzuki T, Karasawa T, Kaneko U, Yamada T, Hasegawa H, Nagata M, Saitoh A.

Hum Pathol. 2014 Aug;45(8):1778-83. doi: 10.1016/j.humpath.2014.03.017. Epub 2014 Apr 18.

PMID:
24856573
8.

Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.

Dong L, Pietsch S, Tan Z, Perner B, Sierig R, Kruspe D, Groth M, Witzgall R, Gröne HJ, Platzer M, Englert C.

J Am Soc Nephrol. 2015 Sep;26(9):2118-28. doi: 10.1681/ASN.2014080819. Epub 2015 Jan 2.

9.

WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.

Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A.

Hum Mol Genet. 2002 Mar 15;11(6):651-9.

PMID:
11912180
10.

WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.

Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA.

Curr Biol. 2001 Nov 13;11(22):1805-9.

11.

New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.

Morrison AA, Viney RL, Saleem MA, Ladomery MR.

Am J Physiol Renal Physiol. 2008 Jul;295(1):F12-7. doi: 10.1152/ajprenal.00597.2007. Epub 2008 Apr 2. Review.

12.

Repression of CMIP transcription by WT1 is relevant to podocyte health.

Moktefi A, Zhang SY, Vachin P, Ory V, Henique C, Audard V, Rucker-Martin C, Gouadon E, Eccles M, Schedl A, Heidet L, Ollero M, Sahali D, Pawlak A.

Kidney Int. 2016 Dec;90(6):1298-1311. doi: 10.1016/j.kint.2016.07.016. Epub 2016 Sep 17.

PMID:
27650733
13.

WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.

Schumacher VA, Schlötzer-Schrehardt U, Karumanchi SA, Shi X, Zaia J, Jeruschke S, Zhang D, Pavenstädt H, Drenckhan A, Amann K, Ng C, Hartwig S, Ng KH, Ho J, Kreidberg JA, Taglienti M, Royer-Pokora B, Ai X.

J Am Soc Nephrol. 2011 Jul;22(7):1286-96. doi: 10.1681/ASN.2010080860. Epub 2011 Jun 30. Erratum in: J Am Soc Nephrol. 2011 Dec;22(12):2332. Pavenstaedt, Hermann [corrected to Pavenstädt, Hermann].

14.

TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.

Sakairi T, Abe Y, Kopp JB.

Nephrol Dial Transplant. 2011 Sep;26(9):2746-52. doi: 10.1093/ndt/gfr061. Epub 2011 Mar 4.

15.

A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis.

Benetti E, Caridi G, Malaventura C, Dagnino M, Leonardi E, Artifoni L, Ghiggeri GM, Tosatto SC, Murer L.

Clin J Am Soc Nephrol. 2010 Apr;5(4):698-702. doi: 10.2215/CJN.05670809. Epub 2010 Feb 11.

16.

The dysregulated glomerular cell growth in Denys-Drash syndrome.

Yang AH, Chen JY, Chen BF.

Virchows Arch. 2004 Sep;445(3):305-14. Epub 2004 Jul 1.

PMID:
15232745
17.

Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.

Swiatecka-Urban A, Mokrzycki MH, Kaskel F, Da Silva F, Denamur E.

Pediatr Nephrol. 2001 Aug;16(8):627-30.

PMID:
11519891
18.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR.

Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.

19.

PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.

Wang D, Li Y, Wu C, Liu Y.

PLoS One. 2011 Feb 24;6(2):e17048. doi: 10.1371/journal.pone.0017048.

20.

Clinical Aspects of WT1 and the Kidney.

Miller-Hodges E.

Methods Mol Biol. 2016;1467:15-21. doi: 10.1007/978-1-4939-4023-3_2.

PMID:
27417956

Supplemental Content

Support Center